WebLY3200882 is a highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). 体外活性. LY3200882 potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and … Web15 dec. 2024 · Purpose: A novel, selective, next-generation transforming growth factor beta (TGFβ) receptor type-1 small molecule inhibitor, LY3200882, demonstrated promising …
LY-3200882: Uses, Interactions, Mechanism of Action - DrugBank
WebApplication In Synthesis of [ 1898283-02-7 ] * All experimental methods are cited from the reference, please refer to the original source for details.We do not guarantee the accuracy of the content in the reference. Downstream synthetic route of [ 1898283-02-7 ] Web5 aug. 2024 · LY-3200882 . LY-3200882 is under investigation in clinical trial NCT04158700 (A Study of LY3200882 and Pembrolizumab in Participants With Advanced Cancer). LY-3200882. Trade Name: LY-3200882: Generic: LY-3200882: Type: Formula: C 24 H 29 N 5 O 3: Weight: Average: 435.528 Monoisotopic: 435.227039814 : Groups: Investigational: birthday 12th
LY3200882 (CAS 1898283-02-7)
Web15 aug. 2024 · In order to rationalize the design idea (), the binding mode of LY-3200882 with TGF-βRI was studied.It was found that N-cyclopropyl-1H-pyrazole showed a strong … WebLY3200882 is a next generation, ATP competitive, potent, highly selective small molecule inhibitor of TGF-β receptor type 1 (TGFβRI). It inhibits the serine-threonine kinase … WebLY 3200882 is a potent, highly selective inhibitor of TGF-β receptor type 1 (TGFβRI). It potently inhibits TGFβ mediated SMAD phosphorylation in vitro in tumor and immune … birthday 123 greetings